| Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer MCU Cheang, SK Chia, D Voduc, D Gao, S Leung, J Snider, M Watson, ... JNCI: Journal of the National Cancer Institute 101 (10), 736-750, 2009 | 3220 | 2009 |
| The clonal and mutational evolution spectrum of primary triple-negative breast cancers SP Shah, A Roth, R Goya, A Oloumi, G Ha, Y Zhao, G Turashvili, J Ding, ... Nature 486 (7403), 395-399, 2012 | 2362 | 2012 |
| Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype MCU Cheang, D Voduc, C Bajdik, S Leung, S McKinney, SK Chia, ... Clinical cancer research 14 (5), 1368-1376, 2008 | 1740 | 2008 |
| Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early … A Schneeweiss, S Chia, T Hickish, V Harvey, A Eniu, R Hegg, C Tausch, ... Annals of oncology 24 (9), 2278-2284, 2013 | 1393 | 2013 |
| Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3 DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... Journal of Clinical Oncology 36 (24), 2465-2472, 2018 | 1091 | 2018 |
| Overall survival with ribociclib plus fulvestrant in advanced breast cancer DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... New england Journal of medicine 382 (6), 514-524, 2020 | 794 | 2020 |
| Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors Y Lou, PC McDonald, A Oloumi, S Chia, C Ostlund, A Ahmadi, A Kyle, ... Cancer research 71 (9), 3364-3376, 2011 | 794 | 2011 |
| Population-based validation of the prognostic model ADJUVANT! for early breast cancer IA Olivotto, CD Bajdik, PM Ravdin, CH Speers, AJ Coldman, BD Norris, ... Journal of Clinical Oncology 23 (12), 2716-2725, 2005 | 713 | 2005 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 701 | 2017 |
| Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 … A Chan, S Delaloge, FA Holmes, B Moy, H Iwata, VJ Harvey, NJ Robert, ... The Lancet Oncology 17 (3), 367-377, 2016 | 685 | 2016 |
| Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution P Eirew, A Steif, J Khattra, G Ha, D Yap, H Farahani, K Gelmon, S Chia, ... Nature 518 (7539), 422-426, 2015 | 679 | 2015 |
| Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with … S Chia, W Gradishar, L Mauriac, J Bines, F Amant, M Federico, L Fein, ... Journal of clinical oncology 26 (10), 1664-1670, 2008 | 673 | 2008 |
| 21-gene assay to inform chemotherapy benefit in node-positive breast cancer K Kalinsky, WE Barlow, JR Gralow, F Meric-Bernstam, KS Albain, ... New England Journal of Medicine 385 (25), 2336-2347, 2021 | 645 | 2021 |
| The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancer SK Chia, CH Speers, Y D'yachkova, A Kang, S Malfair‐Taylor, J Barnett, ... Cancer 110 (5), 973-979, 2007 | 571 | 2007 |
| Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double … J Baselga, SA Im, H Iwata, J Cortés, M De Laurentiis, Z Jiang, CL Arteaga, ... The Lancet Oncology 18 (7), 904-916, 2017 | 562 | 2017 |
| EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer L Hughes-Davies, D Huntsman, M Ruas, F Fuks, J Bye, SF Chin, J Milner, ... Cell 115 (5), 523-535, 2003 | 546 | 2003 |
| Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma SK Chia, CC Wykoff, PH Watson, C Han, RD Leek, J Pastorek, KC Gatter, ... Journal of Clinical Oncology 19 (16), 3660-3668, 2001 | 538 | 2001 |
| Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers S Chia, B Norris, C Speers, M Cheang, B Gilks, AM Gown, D Huntsman, ... Journal of Clinical Oncology 26 (35), 5697-5704, 2008 | 449 | 2008 |
| A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen SK Chia, VH Bramwell, D Tu, LE Shepherd, S Jiang, T Vickery, E Mardis, ... Clinical cancer research 18 (16), 4465-4472, 2012 | 386 | 2012 |
| Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer … R Gray, R Bradley, J Braybrooke, Z Liu, R Peto, L Davies, D Dodwell, ... The lancet 393 (10179), 1440-1452, 2019 | 376 | 2019 |
